MRNA
Moderna·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRNA
Moderna, Inc.
A biotech company pioneering messenger RNA (mRNA) therapeutics and vaccines
Biological Technology
07/22/2016
12/07/2018
NASDAQ Stock Exchange
5,800
12-31
Common stock
325 Binney Street, Cambridge, Massachusetts 02142
Biopharmaceuticals in genetic engineering
Moderna, Inc., was incorporated under the laws of the State of Delaware on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (messenger ribonucleic acid) medicine. Through more than a decade of work at the intersection of science, technology and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective Covid-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset to responsibly change the future of human health, the company strives to deliver the greatest possible impact to people through mRNA medicines.
Earnings Call
Q1/2025
Estimate EPS-3.18
Actual EPS-2.52
Estimate Revenue115.32M
Actual Revenue108.00M
Moderna's Q1 2025: Unraveling Key Contradictions on Vaccine Trials, Market Dynamics, and Regulatory Challenges
May 06,2025 10:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-2.97
Actual EPS-2.13
Estimate Revenue112.96M
Actual Revenue142.00M
Moderna's 2025 Q2 Earnings Call: Key Contradictions in Vaccine Pricing, Clinical Holds, and Efficacy Analysis
Aug 01,2025 12:02
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MRNA has released its 2025 Q3 earnings. EPS was reported at -0.51, versus the expected -2.18, beating expectations. The chart below visualizes how MRNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRNA has released its 2025 Q3 earnings report, with revenue of 1.02B, reflecting a YoY change of -45.44%, and net profit of -200.00M, showing a YoY change of -1638.46%. The Sankey diagram below clearly presents MRNA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
